title: Allicin as a possible adjunctive therapeutic drug for stage II oral submucous fibrosis: a preliminary clinical trial in a Chinese cohort.
abstract: The objective of this study was to investigate the efficacy and safety of allicin in the treatment of stage II oral submucous fibrosis (OSF) in a Chinese patient cohort. A randomized clinical trial was performed. Triamcinolone acetonide (TA) or allicin was injected intralesionally weekly for 16 weeks. Improvements in mouth opening, burning sensation, and oral health-related quality of life were evaluated. Forty-eight subjects completed the study without obvious adverse reactions. At 40 weeks, the net gain in mouth opening was 2.27 ± 0.84 mm in the TA group and 5.16 ± 1.04 mm in the allicin group. Burning sensation improved by 2.79 ± 0.87 in the TA group and by 4.33 ± 1.04 in the allicin group. The OHIP-14 score improved by 4.67 ± 2.94 in the TA group and by 12.58 ± 9.82 in the allicin group. Allicin intralesional injections improved mouth opening, burning sensation, and oral health-related quality of life in these stage II OSF patients. Allicin appears to be a potential adjunctive therapeutic drug.
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China; Institute of Translation Medicine of University of South China, Chenzhou, Hunan, China. Electronic address: jxw0927@163.com.
authors.forename: X
authors.initials: X
authors.lastname: Jiang
authors.affiliation: Institute of Translation Medicine of University of South China, Chenzhou, Hunan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China.
authors.forename: F
authors.initials: F
authors.lastname: Li
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China.
authors.forename: S
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Stomatology, First People's Hospital of Chenzhou, University of China South, Chenzhou, Hunan, China.
authors.forename: G
authors.initials: G
authors.lastname: Sun
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D002681:China; D004220:Disulfides; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009914:Oral Submucous Fibrosis / Q000188:drug therapy*; D011788:Quality of Life; D013441:Sulfinic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D004220:Disulfides; D005938:Glucocorticoids; D013441:Sulfinic Acids; C006452:allicin; D014222:Triamcinolone Acetonide
keywords: allicin; oral submucous fibrosis; treatment; triamcinolone acetonide